Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis.

Huijuan Li,Hedong Han,Chuling Li,Ranpu Wu,Zhaofeng Wang,Yimin Wang,Ping Zhan,Tangfeng Lv,Fang Zhang,Yong Song,Hongbing Liu

Therapeutic advances in medical oncology（2023）

引用 0|浏览4

暂无评分

摘要

Serplulimab plus chemotherapy seems to be superior first-line immunotherapy combination for patients with ES-SCLC. PD-1 + chemo seems to outperform PD-L1 + chemo in PFS.

查看译文

关键词

efficacy, extensive-stage small-cell lung cancer, immunotherapy combinations, network meta-analysis, safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要